IBRUSHIL 120

Product Description

Ibrutinib is the active component of the medicine IBRUSHIL 120. It is a prescription medication used to treat specific blood malignancies and diseases that are associated to them. Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, which inhibits the enzyme's ability to promote the development and survival of cancer cells. IBRUSHIL 120 capsules are taken by mouth once daily on average. Fatigue, diarrhoea, and upper respiratory tract infections are examples of typical adverse effects. It offers disease management and enhances patient outcomes for illnesses such chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia. Throughout treatment, regular medical monitoring is required.

IBRUSHIL 120's features and advantages include:

Features:

1. Ibrutinib: Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is the active component of IBRUSHIL 120.

2. Treatment for certain blood malignancies and related diseases, such as chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia, involves the use of the drug IBRUSHIL 120.

3. IBRUSHIL 120 capsules are administered orally, making it convenient and simple to use.

4. Dosage once daily: The capsules are normally taken once daily, making it easier for patients to follow a dosage schedule.

Benefits:

1. Ibrutinib in IBRUSHIL 120 targets particular enzymes involved in the proliferation of cancer cells, offering targeted therapy.

2. Disease prevention: IBRUSHIL 120 prevents the spread and survival of cancer cells in a variety of blood malignancies.

3. Survival rates are higher: According to clinical research, Ibrutinib treatment can increase both overall survival rates and progression-free survival in some instances of blood cancer.

4. Less severe side effects compared to conventional chemotherapy, ibrutinib is generally well tolerated and has less side effects overall.

5. Ibrutinib has demonstrated advantages in giving patients with persistent blood malignancies with long-term therapeutic alternatives.

6. Ibrutinib can be used in combination with other cancer medications to increase the effectiveness of those therapies.

7. Convenience: Patients receiving treatment can take IBRUSHIL 120 capsules once daily, which is quite convenient.

8. Non-invasive treatment: Because IBRUSHIL 120 is taken orally, patients have the option of a non-invasive treatment.

It is crucial to keep in mind that, despite having many advantages in the treatment of some blood malignancies, IBRUSHIL 120 may also have risks and side effects. During treatment, patients should be regularly watched by medical personnel, and any alarming symptoms should be reported right away for the proper management. Oncologists or other medical professionals skilled in treating blood malignancies should be consulted before choosing a course of treatment. 

IBRUSHIL 120 uses include:

1. IBRUSHIL 120 is used to treat Chronic Lymphocytic Leukaemia (CLL), a malignancy that affects white blood cells.

2. It is also recommended for the treatment of Mantle Cell Lymphoma (MCL), a rare and aggressive non-Hodgkin lymphoma.

3. Waldenstrom Macroglobulinemia: IBRUSHIL 120 is used to treat the uncommon blood malignancy Waldenstrom Macroglobulinemia.

IBRUSHIL 120 side effects include: 

1. Patients may feel weary or weak due to fatigue.

2. Diarrhoea: Diarrhoea is a potential symptom for some people.

3. IBRUSHIL 120 has the potential to make you feel queasy or make you throw up.

4. Diseases of the upper respiratory tract: Patients may be more susceptible to such diseases.

5. Ibrutinib may make it more likely for someone to bruise or bleed.

6. Rash: Some people may experience allergic reactions or skin rashes.

7. Reduced blood cell counts: IBRUSHIL 120 can cause a reduction in platelets, white blood cells, and red blood cells, which raises the risk of bleeding, infections, and anaemia.

8. Ibrutinib has the potential to cause muscle and joint pain.

9. High blood pressure: In some cases, it may cause elevated blood pressure levels.

10. Ibrutinib may, in rare occasions, cause heart rhythm problems.

11. Ibrutinib has been linked to an increased risk of developing atrial fibrillation.

12.Hepatotoxicity: In extremely rare cases, it may result in liver issues and elevated liver enzyme levels.

When using IBRUSHIL 120, patients should be closely watched by medical specialists. Any symptoms that warrant further investigation should be reported right away to the healthcare professional as the medication carries a potential for serious adverse effects. With the help of oncologists or other medical professionals skilled in treating CLL, MCL, and Waldenstrom macroglobulinemia, treatment choices should be made.